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Abstract
Artemisinin (ART) is the recommended first line therapy for treating uncomplicated and drug-resistant Plasmodium
falciparum, the most pathogenic form of malaria. However, treatment failure following ART monotherapy is not uncommon
and resistance to this rapidly acting drug has been reported in the Thai-Cambodian border. Recent in vitro studies have
shown that following treatment with dihydroartemisinin (DHA), the development of ring-stage parasites is arrested for up to
20 days. These arrested (i.e. dormant) rings could be responsible for the recrudescence of infection that is observed
following ART monotherapy. To develop a better understanding of the stage-specific effects of ART and determine if
dormancy occurs in vivo, the ART derivative artesunate (AS) was used to treat mice infected with the synchronous rodent
malaria parasites P. vinckei petteri (non-lethal) and P. v. vinckei (lethal). Results show that in both the non-lethal and lethal
strains, ring-stage parasites are the least susceptible to treatment with AS and that the day of treatment has more of an
impact on recrudescence than the total dose administered. Additionally, 24 hrs post-treatment with AS, dormant forms
similar in morphology to those seen in vitro were observed. Finally, rate of recrudescence studies suggest that there is a
positive correlation between the number of dormant parasites present and when recrudescence occurs in the vertebrate
host. Collectively, these data suggest that dormancy occurs in vivo and contributes to recrudescence that is observed
following AS treatment. It is possible that this may represent a novel mechanism of parasite survival following treatment
with AS.
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Introduction
Malaria is a mosquito-borne disease caused by a protozoan
parasite from the genus Plasmodium. There are more than 100
species of Plasmodium that are transmitted by the bite of an infected
female Anopheles mosquito, but only five are known to infect
humans: P. falciparium, P. vivax, P. ovale, P. malariae, and P. knowlesi.
Malaria is especially dangerous to pregnant women and small
children, and in endemic countries, it is an important determinant
of perinatal mortality [1]. P. falciparum malaria alone is responsible
for over 800,000 deaths a year, with many of these fatalities
occurring in infants in Africa [2].
Artemisinin (ART) and its derivatives are the only remaining
drugs that are effective against severe malaria and multi-drug
resistant malaria [3]. ART is derived from the Chinese herb
Artemesia annua (sweet wormwood), which has been used success-
fully to treat malaria associated fevers since 138 BC [4]. In vivo,
ART produces fast parasite and fever clearance, is well tolerated,
and has an important role in the treatment of severe and cerebral
malaria [5]. However, what is not understood about this powerful
anti-malarial is that when given alone, there is a high frequency of
recrudescence [6,7]. This high rate of recrudescence has prompted
the World Health Organization (WHO) and the International
Artemisinin Study Group to recommend that uncomplicated P.
falciparum malaria be treated with ART or its derivatives in
combination with another effective blood schizontocide to delay
the selection of resistant strains [8]. While many advocate the use
of Artemisinin-based combination therapy (ACT) to delay the
development of resistance to the remaining armory of effective
drugs, a major impediment to using ACT is its cost [9]. Currently,
the cost per treatment is $1.20–2.50 per person, as compared to
$0.10–0.20 per person for chloroquine and sulfadoxine-pyrimeth-
amine [9]. Even with ACT, there are still issues with treatment
failure and recrudescence of infections [10].
Recrudescence in falciparum malaria is considered a sign of
treatment failure and it forces a shift to more potent drugs or drug
combinations [11]. Studies by Nakazawa et al [11] suggest that
treatment failure may be due to either resistant parasite strains that
are selected by drug treatment or blood levels of the drug that are
insufficient to further suppress the parasite. Those studies also
suggest that a small percentage of the parasites may be in a
dormant state and are unaffected by drug treatment. When such
treatment is discontinued, these parasites resume normal devel-
opment, resulting in a detectable parasitemia [12,13,14]. In a
separate in vitro study, P. falciparum exposed to artesunate (AS) or
dihydroartemisinin (DHA) demonstrated that development of
early ring-stage parasites was rapidly interrupted, and that these
parasites survived in a dormant form for up to 20 days before
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dormancy recovery rates and duration produced treatment failure
rates comparable to those reported in the field [15]. More recent
microarray studies demonstrate these dormant rings remain in a
state of transcriptional arrest at the ring stage before resuming
growth approximately 7 days later, further supporting the dormancy
hypothesis [14],[Tucker et al 2011, submitted for publication].
However, ART induced dormancy and its role in treatment failure
in vivo has not been demonstrated and characterized.
In this study, the rodent malaria models P. vinckei petteri (non-
lethal strain) and P. vinckei vinckei (lethal strain) were used to
investigate the stage-specific effects of AS on malaria parasites in
vivo. These parasites were chosen because of their ability to remain
synchronous in vivo, thus allowing for testing the effect of AS drug
action on specific parasite stages. Previous studies have found that
the ring and trophozoite stages of P. v. petteri were the most
susceptible to treatment with the oil-soluble artemether [16]. Our
results suggest that ring-stage parasites are the least susceptible to
treatment with the water soluble AS and that the effects are
dependent upon when the drug is administered. Additionally,
dormancy recovery studies reveal that there appears to be a
correlation between the number of dormant parasites present
following drug exposure and the timing of recrudescence. These
studies not only provide a better understanding about the effects
that treatment with AS has on specific parasite stages, but also
provide insight into possible reasons for recrudescence and
subsequent treatment failures.
Results
The stage-specific effects of a single dose of AS in P. v.
petteri and P. v. vinckei
The goal of these studies was to assess the effects of a single dose
of AS (64 mg/kg) on P. vinckei. There were five experimental
groups infected with either P. v. petteri (n=8 per group) or P. v.
vinckei (n=5 per group). To control for variations of infection, one
Figure 1. Experimental design for the stage-specific studies. Donor mice were used to infect one batch of 25 or 40 experimental mice with
either P. vinckei vinckei or P. vinckei petteri, respectively. Mice then were randomly separated into groups of 5 consisting of untreated, artesunate
treated (AS) rings, trophozoites (trophs), and schizonts. Amodiaquine treated parasites were included as a positive drug control. Parasitemia were
monitored for 30 days.
doi:10.1371/journal.pone.0026689.g001
The Effects of Artesunate In Vivo
PLoS ONE | www.plosone.org 2 October 2011 | Volume 6 | Issue 10 | e26689batch of experimental mice were inoculated with parasites at the
same time (Figure 1). Mice then were dosed according to a
previously published time-line for parasite development [17,18] to
allow stage-specific treatment of rings, trophozoites, and schizonts.
Figures 2A and B show examples of what the parasite stages
look like before and after treatment. Effectiveness of AS treat-
ment was determined by assessing mean peak parasitemia for
the non-lethal strain P. v. petteri and survival for the lethal strain
P. v. vinckei.
Rings. Mice infected with P. v. petteri and treated with one
dose of AS when rings were present had a mean peak parasitemia
of 13.50%63.16 on day 7 post-infection (PI) (Figure 3A). This
peak parasitemia was found to be significantly lower from that
observed for the untreated mice on the same day (35.36614.0,
Dunnett’s multiple comparison test, p,0.001). For the treated
rings, the peak on day 7 was followed by parasite clearance on day
14 PI. A recurrence of infection on day 27 PI was due to one
mouse with an 8.6% parasitemia that cleared on day 29 PI and
remained clear until the end of the experiment on day 30 PI
(Figure 3B). In P. v. vinckei-infected mice, the untreated group had a
median survival of 7.0 days, whereas mice treated with one dose of
AS had a median survival of 9.0 days (Figure 3C).
Trophozoites. P. v. petteri-infected mice treated during the
trophozoite stage had a significantly lower mean peak parasitemia
of 7.65%62.114 (Dunnett’s multiple comparison test, p,0.001)
on day 8 PI when compared to the untreated (Figure 3A). One
additional peak was observed on day 14 PI (4.6%) due to one
mouse with a 40% parasitemia (Figures 3B). By day 18 PI, all mice
showed complete clearance of parasitemia until the end of the
study. In P. v. vinckei-infected mice, the final mouse did not die
until day 13.5; however, like the treated rings, groups dosed
during the trophozoite stage had a median survival of 9.0 days
(Figure 3C).
Schizonts. P. v. petteri-infected mice treated during the
schizont stage had a mean peak parasitemia of 11.30%62.78 on
day 7PI and cleared on day 16 PI (Figure 3A). This peak
Figure 2. P. v. vinckei morphology in mice before treatment and 24 hr following treatment with artesunate. A. Two representative
images are shown for each stage of development in vivo. Ring-stage (R), young trophozoite (Y-troph), mid-term trophozoite (M-troph), old
trophozoite (O-troph), and schizont. (SCH). B. Treated ring-stage parasites (top row) have a condensed nucleus and pyknotic appearance. Older
parasite stages treated with artesunate (bottom row) appear to have an absence of hemozoin and loss of membrane integrity.
doi:10.1371/journal.pone.0026689.g002
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multiple comparison test, p,0.001). Low-level recrudescence
occurred in the follow-up period of thirty days (Figure 3B).
Studies with the lethal strain P. v. vinckei that were initiated during
the schizont stage resulted in a median survival of 9.0 days
(Figure 3C).
Overall, for P. v. petteri-infected mice, all treatment groups had
significantly lower peak parasitemias when compared to the
untreated (Dunnett’s multiple comparison test, p,0.001). No
differences were observed in peak parasitemia between the treated
trophozoites and schizonts; however, both stages had significantly
lower peak parasitemias than the treated rings (Dunnett’s multiple
comparison test, p,0.05). Mice treated with the control drug
amodiaquine remained clear for the duration of the study. For P. v.
vinckei-infected mice, there were differences between the survival
times of the different experimental groups (log rank test, chi sq
13.62, df 1.0, p,0.0001). There was no difference in survival
following one dose of AS when compared to the untreated groups;
however, treatment with one dose of chloroquine (control drug)
resulted in a median survival of 16 days, which was significantly
higher than the untreated (Dunnett’s multiple comparison test,
p,0.05).
The effects of repeated dosing on P. v. vinckei ring-stage
parasites in vivo
Consecutive dosing with AS. To assess the effects of
consecutive doses of AS on parasite recrudescence, P. v. vinckei-
infected mice were treated with a total dose of 256 mg/kg divided
over 2–4 days (Table 1). One batch of 50 mice were inoculated IP
with P. v. vinckei and then randomly divided into ten treatment
groups (n=5 per group; Figure 4). Untreated mice had a median
survival rate of 8.5 days, whereas, mice treated with one 256 mg/
kg dose of AS had a median survival of 14.5 days (Figure 5A).
Following repeated exposure to AS on 2 (128 mg/kg/day) and 4
(64 mg/kg/day) consecutive days the median survival was 16 and
18 days, respectively (Figure 5A). When compared to the
untreated, three consecutive days of treatment was the most
effective regimen with 70.0% of the mice surviving until day 30 PI
(Dunnett’s multiple comparison test, p,0.01; Figure 5A).
Variable dosing with AS. The effects of variable dosing on
parasite recrudescence were assessed following treatment with a
total dose of 256 mg/kg of AS divided equally over 2 or 3 days.
Mice treated on days 3 and 5 PI had a median survival of 17 days
(Figure 5B). Treatment on days 3, 4, 7 and 3, 5, 7 resulted in a
median survival of 24 and 18 days, respectively (Figure 5B).
Treatment on days 3 and 7 had the highest survival rate when
compared to the untreated, with 80.0% of the mice surviving
until day 30 PI (Dunnett’s multiple comparison test, p,0.05;
Figure 5B).
Comparison of P. v. petteri and P. v. vinckei. Data from
both the consecutive and variable studies were compared to results
obtained from a pilot study using the non-lethal P. v. petteri
(Table 2). In the pilot study, because P. v. petteri is a non-lethal
strain, peak parasitemia was used as a measure of AS effectiveness.
All mice received 64 mg/kg/day of AS which resulted in a
different total dose for each treatment group (Table 3). The most
effective treatment regimens, because they had the lowest peak
parasitemias of 1.21% and 1.58%, were on days 3, 4 and 7 and for
4 consecutive days, respectively (Table 2). Studies with the lethal
strain revealed that P. v. vinckei-infected mice dosed for 3
consecutive days (85.3 mg/kg/day) had a survival rate of 70%
which was significantly higher than the untreated (Dunnett’s
multiple comparison test, p,0.01; Table 2). For the variably dosed
groups, mice treated on days 3 and 7 PI (128 mg/kg/day) had the
Figure 3. The stage-specific effects of a single dose of AS.
A. Plasmodium vinckei petteri-infected mice (n=8 mice per group)
were treated with one dose of AS (64 mg/kg). Comparison of peak
parasitemias revealed that all treated groups had significantly lower
peak parasitemias when compared to the untreated control (Dunnett’s
multiple comparison test, p,0.001). *=statistically significant differ-
ence. B. Assessment of average daily parasitemias showed that the ring
stage had the highest average parasitemia when compared to treated
trophozoites and schizonts. Both the ring and trophozoite groups had a
secondary peak on days 27 and 14 PI, respectively. Overall, the treated
trophozoites took the longest to clear and had the lowest average
parasitemia. Data are means 6 SD. C. Mice infected with the lethal
strain P. v. vinckei (n=5 mice per group) were treated with one dose of
AS (64 mg/kg). The median day of survival for untreated mice, and mice
treated when mostly rings, trophozoites, or schizonts were present was
7.0 and 9.0, respectively. No significant difference in survival was
observed among the treated groups.
doi:10.1371/journal.pone.0026689.g003
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(Dunnett’s multiple comparison test, p,0.05; Table 2). Overall,
the data show that the day of treatment, rather than the total dose
administered, is more important for parasite clearance and/or host
survival when treating with AS.
Dormant parasite recrudescence
In vivo dormant parasite recrudescence studies were performed
with P. v. vinckei to determine if the number of dormant parasites
present in the vertebrate host directly correlates with observance of
recrudescence. Additionally, given that the spleen plays a role in
clearance of malaria parasites [7,19,20], differences in clearance of
dormant parasites in intact and asplenic mice were evaluated. In
this study, donor mice were infected with P. v. vinckei and when
parasitemia were .10.0% with mostly rings present, mice were
treated with AS. Twenty-four hours post-treatment, blood was
harvested from mice via cardiac puncture and smears were
prepared. Analysis of Giemsa-stained blood smears revealed that a
majority of the treated rings were dormant, as defined by small
rounded forms with a dark staining nucleus (Figure 2B; top row).
Experimental mice, intact (n=30) and splenectomized (n=30),
were injected with a range of dormant parasites (40 to 4610
6
dormant parasites/100 ml) and rate of recrudescence (time to
reach 5.0% parasitemia) was compared between the two groups
using Giemsa-stained thin smears. Intact (n=10) and asplenic
mice (n=10) injected with untreated ring-stage parasites (40 and
4610
6) were included as controls. Percent survival was determined
for the entire 30 day assay (Table 4).
Results revealed that, for intact and asplenic mice, there is a
positive correlation between the numbers of dormant parasites
present and when parasite recrudescence occurs (Figures 6A and
B). Overall, the survival curves of the intact (log rank test, chi sq
14.45, df 1.0, p,0.0001) and asplenic (log rank test, chi sq 28.87,
df 1.0, p,0.0001) mice were significantly different. The average
survival of the intact mice and asplenic mice was 20.0% and 7.5%,
respectively (Figures 7A and B). However, mice injected with
4610
1 dormant parasites, were the only group to have a
significantly higher survival rate (100%) when compared to mice
infected with 4610
6 untreated rings (Dunnett’s multiple compar-
ison test, p,0.05; Table 4). Additionally, as parasites began to
recover, ring-stage parasites were the predominant stage present,
suggesting that it is the activated, formally dormant rings that are
responsible for the recrudescence observed following artemisinin
treatment (Figures 8 A–H).
Discussion
Stage-specific effects
Based on results from previous in vitro assays, we hypothesized
that treated ring-stage parasites would have a delay in the pre-
patent period due to the formation of dormant ring forms,
trophozoites would be killed, and schizonts would be delayed in
the time to reach the euthanasia end point of 40.0% parasitemia.
Therefore, in these studies the stage-specific effects of a single dose
of AS in two synchronous rodent malaria models, P. v. petteri (non-
lethal) and P. v. vinckei (lethal), were examined.
Results showed that there was no difference in average
parasitemia among the treated groups in the stage-specific studies.
However, the average peak parasitemia data suggest that the
trophozoite stage was most susceptible to treatment with AS,
followed by the schizonts stage. Both stages were more susceptible
to AS treatment than ring-stage parasites (Figure 3A). These
findings differ from those found in studies by Caillard et al [16],
which indicated that rings and young trophozoites were the most
susceptible to treatment with an artemisinin derivative. Possible
reasons for the differences seen in this study versus the Caillard
study are that they used arteether, an oil-soluble compound, which
was injected subcutaneously and as a result had a prolonged
exposure in the blood stream rather than the more rapid
elimination of AS following oral administration [21]. More
importantly, Caillard et al [16] only followed the parasitemias
for 48 hours, whereas we saw recrudescence well after this time
period. Another possible reason for the differences in these studies
is the self-clearing phenotype exhibited by P. v. petteri. Studies have
shown that untreated infections with P. v. petteri peaked on day 10
PI and spontaneously cleared on day 20 PI [22]. Although
untreated infections in this study reached greater than 40%
parasitemia before the experimental groups, it is important to note
that the peak parasitemia occurred on the same day. It is possible
that we would have observed a similar trend in our untreated
groups as the experimental groups had they not been euthanized
at the cutoff parasitemia of 40.0%.
Table 1. Artesunate dosing schedule for mice infected with P. v. vinckei.
Group Days Dosed Schedule of Dosing Mice per Group Dose per Day (mg/kg) Total Dose (mg) Dosing Rationale
1 Untreated N/A 5 N/A N/A Infection Control;
Did not receive treatment
2 3 One day 5 256 256 One day regimen
3 3–4 Two days, consecutive 5 128 256 Two day regimen
4 3–5 Three days, consecutive 5 85.3 256 Standard three day regimen
5 3–6 Four days, consecutive 5 64.0 256 Four day regimen
6 3 and 5 Two days, variable 5 128 256 Two day regimen
7 3,4,7 Three days, variable 5 128 256 Day 4 PT (Day 7 PI)*
8 3,5,7 Three days, variable 5 85.3 256 Day 4 PT (Day 7 PI)*
9 3 and 7 Two days, variable 5 128 256 Day 4 PT (Day 7 PI)*
10 3 Amodiaquine 5 64.0 256 Drug control
There were ten experimental groups. All groups except the untreated received a total dose of 256 mg/kg of AS.
*=Time point chosen because previous in vitro studies with P. falciparum showed that following treatment with dihydroartemisinin (DHA), dormant ring-stage parasites
start to resume growth (i.e. normal parasite stages observed) on days 4–5 post-treatment (PT). We wanted to assess how treatment at this time-point would affect
parasite recrudescence in vivo. N/A=not applicable; PT=post-treatment; PI=post-infection.
doi:10.1371/journal.pone.0026689.t001
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uncomplicated malaria case in which the patient has a
parasitemia, but does not exhibit the pathology associated with
severe disease. Perhaps the lingering parasites are suppressed by
the action of AS long enough for the host immune response to be
activated and clear the parasitemia. These factors make this model
ideal for studying the effects of drug treatment in conjunction with
a host immune response [23].
This is not the case for the lethal strain P. v. vinckei, to which
immunity can only be attained from prior exposure [18]. To
further evaluate the stage-specific effects of AS in the absence of a
rapid host-immune response, the synchronous rodent malaria
parasite P. v. vinckei was used. Previous studies used P. v. vinckei to
examine immune mechanisms that must act quickly to protect
against death [18,24]. As expected, our studies showed that with
this lethal strain, regardless of the stage of development, a single
dose of AS is not sufficient to control a rise in parasitemia. This is
not surprising, as others have found that treatment with AS does
not cure rodent malaria infections [25]. Additionally, recrudes-
cence also has been observed in malaria-infected patients treated
with therapeutic (i.e. curative) doses of AS for multiple days [8,26].
Accordingly, additional experiments were conducted to assess how
multiple doses of AS would impact the development of P. v. vinckei
ring-stage parasites.
Figure 4. Experimental design for the repeated dosing studies. Donor mice were used to infect one batch of 50 experimental mice with P.
vinckei vinckei. Mice then were randomly separated into groups of 10 containing 5 mice each and dosed on different days.
doi:10.1371/journal.pone.0026689.g004
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In this study, we characterized the effects of different dosing
regimens with AS using the rodent malaria model P. v. vinckei.
Others have shown that artemisinin derivatives induce dormancy
in ring-stage parasites [13] and our goal was to determine the
effects of repeated dosing on dormancy. We hypothesized that in
dormant ring form, parasites would not be affected by additional
drug treatment. Additionally, because previous in vitro studies have
shown that dormant rings begin to recrudesce around day 7–9 PT
(3–4 erythrocytic cycles PT), we wanted to determine how dosing
on day 7 PI (i.e. 4 erythrocytic cycles PT) in vivo would affect
treatment outcome. Therefore, for this study, we compared a
standard three-day regimen with variable treatment times to
determine if the total dose administered or day of drug
administration would affect parasite clearance and recrudescence.
All mice received the same total dose of 256 mg/kg (Table 1)
and results indicate that one single dose of AS (256 mg/kg) is not
sufficient to control a rise in parasitemia. Overall, mice that were
treated for 3 consecutive days (85.3 mg/kg/day) and on days 3
and 7 PI (128 mg/kg/day) had the highest survival rates (Table 2).
In comparison, a pilot study using the non-lethal strain P. v. petteri
showed that treatment for 4 consecutive days (256 mg/kg total)
and on days 3,4,7 (192 mg/kg total) were the most effective
(Table 2). Interestingly, although mice in the non-lethal study
received different total doses (Table 3), overall the data suggest
that the day of treatment with AS is more important than the total
dose administered. Additionally, it appears that in both strains,
dosing on day 4 PT (day 7 PI) was the most effective for controlling
parasitemia. A possible explanation for this finding is that, on day
4 PT, dormant parasites may be starting to recover and drug
administration at this time arrests newly activated ring-stage
parasites. Additionally, Teuscher et al [13] showed that only a
fraction of dormant ring stages survive, therefore it is likely that
treating with AS on day 4 PT was sufficient to eradicate the
remaining parasites.
Dormant parasite recrudescence
Previous studies by Teuscher et al [13] have shown that
following treatment with AS, P. falciparum ring-stage parasites
become dormant and approximately 0.001–1.313% recover to
Figure 5. The effects of repeated dosing with AS on P. v. vinckei-
infected mice. Mice were treated with a total dose of 256 mg/kg of AS
and monitored for recrudescence (n=5 mice per group). A. Mice
treated for three or four consecutive days had the highest percent
survival (70%) when compared to the untreated (Dunnett’s multiple
comparison test, p,0.01). B. In the variable group, mice treated on days
3 and 7 post-infection (PI) had the highest percent survival (80%) when
compared to the untreated (Dunnett’s multiple comparison test,
p,0.05).
doi:10.1371/journal.pone.0026689.g005
Table 2. Experimental survival rates using P. v. vinckei (Pvv), a lethal strain, compared to peak parasitemias from a previous study
using P. v. petteri (Pvp), a non-lethal strain.
Pvv-LETHAL Pvp-NON-LETHAL
Group Day Number of doses % survival Peak Parasitemia Day of Peak
1 Untreated N/A 0% 35.18% 9 PI
2 3 1 20% 12.24% 9 PI
3 3–4 2 40% 6.48% 12 PI
43 – 5 3 70%* 4.08% 19 PI
53 – 6 4 4 0 % 1.58% 17 PI
6 3 and 5 2 10% 2.40% 10 PI, 27 PI
7 3,4,7 3 50% 1.21% 31 PI
8 3,5,7 3 40% 3.41% 7 PI
9 3 and 7 2 80%* 7.08% 9 PI
10 Amodiaquine 1 40% 0.70% 19 PI
There were five mice per group in the lethal and non-lethal pilot studies. The most effective regimens in comparison to the untreated group are in bold.
*=p,0.05; Dunnett’s multiple comparison test; N/A=not applicable.
doi:10.1371/journal.pone.0026689.t002
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recovery from dormancy was found to be dose-dependent. To
determine if this same phenomenon occurs in vivo, dormant
parasite recovery (time to reach .5.0% parasitemia) was assessed
using P. v. vinckei. Results showed that dormant forms, similar to
those found in vitro, are present in treated mice and that the day of
parasite recovery is positively related to the number of dormant
parasites present in intact mice; however, this was more variable
in asplenic mice. Based on our experimental design we cannot
definitively calculate recovery rates. However, we can assume that
because groups injected with 40 parasites did not recover, that the
recovery rates are in the order of 1 in 400 dormant parasites
(0.25%) which are comparable to those found in previous studies
[13].
Role of the spleen. Approximately 5.0% of the blood that is
circulated through the body goes to the spleen and on average,
RBCs cross the spleen every 20 minutes [27]. When patients are
infected with malaria, intra-erythrocytic parasite development
results in remodeling of both infected and non-infected RBCs [20].
The spleen filters these altered RBCs and by doing so may
increase anemia thereby, reducing high parasite loads associated
with severe malaria infections [20]. Studies by Newton et al [28]
suggest that this splenic-pitting is responsible for a majority of the
parasite clearance that is seen in patients following artemisinin
treatment.
Asplenic individuals living in falciparum endemic regions,
exhibit more frequent fevers, higher parasitemias, and longer
parasite clearance times following treatment with antimalarials
such as artemisinin [29,30]. Studies using P. berghei-infected mice,
found that animals with full splenectomies had parasitemias
double those found in intact and partially splenectomized mice
[31]. Additionally, when Moore et al [32] assessed parasite
clearance in DHA-treated intact and asplenic mice, it was found
that the capacity to clear parasites was reduced in the asplenic
population. Similarly, our studies showed that dormant parasites
required less time to recover when injected into splenectomized
mice and that overall survival of asplenic mice was lower than in
the intact group. These data confirm the role of the spleen in
clearance of parasites following treatment, yet also demonstrate
the possible evasion of spleen pitting of the dormant rings.




Group Parasites per 100 ml Intact (n=5) Asplenic (n=5) Intact (n=5) Asplenic (n=5)
Untreated 4610
6 00 3 . 2 61.1 4.062.3
Untreated 4610
1 20 0 6.064.4 5.861.1
Dormant 4610
6 00 6 . 6 61.3 7.661.5
Dormant 4610
5 20 0 5.463.1 7.061.0
Dormant 4610
4 00 8 . 0 60.0
a 8.260.4
Dormant 4610
3 00 8 . 6 60.5
a 5.865.3
Dormant 4610
2 20 20 8.464.8
a 4.466.1
Dormant 4610
1 100 40 N/A N/A
There were a total of 16 experimental groups with five mice per group (n=5). Untreated P. v vinckei parasites were injected into experimental mice using quantities
from the lowest and highest dose in the dormant parasite dilution series.
aMeans significantly different to untreated 4610
6, p,0.05; Dunnett’s multiple comparison test. N/A=never reached greater than 5%. Data are means 6SD.
doi:10.1371/journal.pone.0026689.t004
Table 3. Artesunate dosing schedule for mice infected with P. v. petteri.
Group
Days
Dosed Schedule of Dosing Mice per Group Dose per Day (mg/kg) Total Dose (mg) Dosing Rationale
1 Untreated N/A 5 N/A N/A Infection Control; Did not receive treatment
2 3 One day 5 64 64 One day regimen
3 3–4 Two days, consecutive 5 64 128 Two day regimen
4 3–5 Three days, consecutive 5 64 192 Standard three day regimen
5 3–6 Four days, consecutive 5 64 256 Four day regimen
6 3 and 5 Two days, variable 5 64 128 Two day regimen
7 3,4,7 Three days, variable 5 64 192 Day 4 PT (Day 7 PI)
8 3,5,7 Three days, variable 5 64 192 Day 4 PT (Day 7 PI)
9 3 and 7 Two days, variable 5 64 128 Day 4 PT (Day 7 PI)
10 3 Amodiaquine 5 64 64 Drug control
There were ten experimental groups. Each group received 64 mg/kg/day of AS. N/A=not applicable; PT=post-treatment; PI=post-infection.
doi:10.1371/journal.pone.0026689.t003
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warranted.
Summary
We described for the first time the presence of dormant asexual
forms in vivo following treatment with AS. It is unclear whether
this phenomenon is conserved solely to AS; therefore, future
studies should investigate if other artemisinin derivatives and
antimalarials produce these dormant forms and if recrudescence
is observed. Additionally, because of the differences in response
between the non-lethal and lethal strains, future studies should
include a comparison of the number of dormant parasites that
are produced by a non-lethal versus a lethal stain. This would
help determine if there is a correlation between the number of
dormant parasites, the severity of disease, and the effectiveness of
treatment. If there is a difference, perhaps a change in the
recommended treatment strategies needs to be addressed based
on the type of infection presented. Finally, studies investigating
the mechanism behind dormancy should also be conducted.
These findings strengthen the need to use ACT to reduce the
possibility of recrudescence following artemisinin monotherapy
and provide valuable information for optimal dosing regimens in




This study was conducted in compliance with the Guide for the
Care and Use of Laboratory Animals of the National Research
Council for the National Academies. The protocol was approved
by the University of South Florida Institutional Animal Care
and Use Committee (IACUC Protocol Number: R 3655). The
numbers of animals used were the minimum required for
obtaining scientifically valid data. Experimental procedures were
designed to minimize harm and included predefined parasitolog-
ical endpoints to avoid unnecessary suffering.
Animals and Parasites
All mice used in these experiments were female ICR outbred
mice (average weight was approximately 21g) obtained from
Harlan (Fredrick, MD). The rodent malaria parasites P. v. petteri
4BS2 (Malaria Research and Reference Reagent Center, Manas-
sas, VA) and P. v. vinckei ATCC 30091 (American Type Culture
Collection, Rockville, MD) were used for these studies. These
parasites were chosen because they remain highly synchronous in
vivo, allowing for treatment of specific parasite stages. P. v. petteri
results in a non-lethal infection and is often used to study immune
mechanisms [23]. P. v. vinckei, which causes a lethal infection, is
Figure 6. Rate of dormant parasite recrudescence in intact and asplenic mice. Rate of recrudescence was defined as the time to reach
.5.0% parasitemia following injection of normal untreated or dormant parasites (n=5 mice per group). Data are shown as mean total parasitemia
+SD versus time. A. In the intact group, rate of recrudescence from dormancy occurred in a dose-dependent manner, with the highest dilution
recovering faster. B. In the asplenic group, rate of recrudescence occurred in a dose-dependent manner from 4610
4 to 4610
6, after which the
separation is not as well-defined. DORM=dormant parasites.
doi:10.1371/journal.pone.0026689.g006
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[23]. Both strains are chloroquine sensitive.
Drugs
The AS (AS), chloroquine, and amodiaquine (AMO) used in
these studies were obtained through Sigma (St. Louis, MO). The
drugs for these studies were reconstituted to the required dose
needed for each experiment in ddH20 or 0.5% hydroxyethylcellu-
lose (HEC). Drugs were administered with an oral gavage cannula.
Inoculation of malaria parasites
Donor mice were infected intra-peritoneally (IP) with P. v. petteri
or P. v. vinckei parasites obtained from cryopreservation. Blood
from donor mice was obtained via cardiac puncture, erythrocytes
were counted, and parasitemia determined. Different parasite
concentrations were tested in pilot studies and it was determined
that 1610
6 P. v. petteri and 1610
3 P. v. vinckei parasites were optimal
for these studies. Experimental mice were infected IP with 0.1 ml
of parasites using a 1.0 ml syringe and a 26 gauge needle.
Determination of parasitemia
Parasitemias were monitored by daily microscopic examination
of methanol fixed blood smears from mice tail veins. Smears were
stained with 20.0% Giemsa for 20 minutes, rinsed, and dried prior
to viewing. Approximately 600 red blood cells (RBC) per
experimental slide were counted and parasitemias, as well as
stages present on examination, were recorded. Mice were
euthanized when parasitemias were $40.0%, according to
IACUC regulations.
For the repeated dosing studies, parasitemias were monitored
daily by fluorescence activated flow sorting using SYBR green, as
previously described [33]. Briefly, one drop of mouse tail blood
was collected into 50 ml of heparin (10 IU) in a 96-well microtiter
plate. Samples then were incubated in the dark with 30 mlo f
SYBR Green I (1:1000 in PBS) for 30 minutes at 37uC. Following
the incubation, 150 ml of PBS was added to each well and the
samples were mixed. Samples then were diluted 1:10 in PBS and
transferred in triplicate to a new 96-well plate for flow analysis.
The Accuri C6 Flow Cytometer (Accuri Cytometers Inc., Ann
Arbor, MI) was used to acquire 100,000 events per sample. Initial
gating was carried out using unstained, non-infected and stained,
non-infected mouse blood to account for erythrocyte auto-
fluorescence and SYBR green background staining, respectively.
To confirm flow cytometry readings, parasitemias also were
calculated via microscopic examination as described previously.
In vivo studies
To assess the effects of AS on specific malaria stages in a non-
lethal and lethal strain, P. v. petteri and P. v. vinckei were used,
respectively. Timing for drug administration was based on
previously published studies [16,17]. Figure 2A illustrates the
characteristics and stages present during dosing.
The stage-specific effects of a single dose of AS on
recrudescence. For this study one batch of 40 mice were
Figure 7. Intact and asplenic mouse survival following exposure to dormant P. v. vinckei parasites. Mice were exposed to varying
numbers of untreated and dormant (dorm) parasites (n=5 mice per group). A. Only 20.0% of intact mice exposed to 40 normal untreated parasites,
and 4610
2 and 4610
5 dormant parasites survived until day 30 post-infection (PI). All mice exposed to 40 dormant parasites survived unto day 30 PI.
B. Asplenic mice exposed to 4610
2 and 40 dormant parasites had a 20.0% and 40.0% survival rate, respectively.
doi:10.1371/journal.pone.0026689.g007
The Effects of Artesunate In Vivo
PLoS ONE | www.plosone.org 10 October 2011 | Volume 6 | Issue 10 | e26689infected IP with P. v. petteri and then separated into five treatment
groups (n=8 mice per group; Figure 1). Groups consisted of
untreated rings (infection control), as well as mice treated with one
dose of AS (64 mg/kg) when rings, mid-term trophozoites, or
schizonts were highly predominant. For the drug control, a group
of mice were treated during the ring stage with 64 mg/kg AMO.
Treatment was initiated on day 3 PI when the mean parasitemia
was $0.32%. Slides were prepared on days 1–10 PT and then
every other day until day 20, followed by days 25, 27, and finally
day 30 PT. This study was performed three times with the same
treatment group comparisons performed within each replicate.
For the P. v. vinckei experiment, one batch of 25 mice were
inoculated IP. There were five groups (n=5 mice per group)
randomly divided into treated rings, mid-term trophozoites, and
schizonts. Control groups consisted of untreated and CQ treated
(64 mg/kg; drug control) mice.
The effects of repeated dosing on P. v. vinckei ring-stage
parasites in vivo. One possible outcome of treatment with AS
is that when parasites enter dormancy they will be less affected by
repeated exposure to the drug. To test this theory, P. v. vinckei ring-
stage parasites were repeatedly exposed to AS either on
consecutive or variable days (Table 1). One batch of 50 mice
Figure 8. Primary stages present during dormant parasite recrudescence in intact mice. The average parasitemia versus time in relation
to the number of dormant parasites are shown in the figure (n=5 mice per group). Rate of recrudescence from dormancy was defined as the average
time to .5.0% parasitemia. In all treatment groups, with the exception of the untreated 4610
6, rings are the predominant stage present as parasites
begin to recover. A (untreated 4610
6), B (untreated 4610
1), C (dorm 4610
6), D (dorm 4610
5), E (dorm 4610
4), F (dorm 4610
3), G (dorm 4610
2) and
H (dorm 4610
1). Ring (R), young trophozoite (YT), mid-term trophozoite (MT), old trophozoite (OT), and schizont (SCH).
doi:10.1371/journal.pone.0026689.g008
The Effects of Artesunate In Vivo
PLoS ONE | www.plosone.org 11 October 2011 | Volume 6 | Issue 10 | e26689were infected with P. v. vinckei and then separated into ten groups
(n=5 mice per group; Figure 4). In a pilot study, P. v. petteri ring-
stage parasites treated with four doses of 64 mg/kg of AS resulted
in a significant increase in survival when compared to the
untreated control. Therefore, all mice in this study were treated
with a total of 256 mg/kg of AS. Group 4 represents a normal
three-day regimen of AS and groups 7–9 were chosen to
determine if dosing on day 4 PT (day 7 PI), when dormant
parasites are expected to recrudesce, would lengthen the time to
reach the euthanasia end point of $40% parasitemia when
compared to the untreated control. Control groups consisted of
untreated and amodiaquine treated (64 mg/kg; drug control)
mice. This study was performed twice with the same treatment
group comparisons performed within each replicate.
Dormant parasite recrudescence. Parasite recrudescence
from dormancy (time to reach .5% parasitemia) was assessed in
vivo using P. v. vinckei. To avoid parasite clearance by the spleen
and maximize the number of dormant parasites, female ICR
splenectomized mice (15–20 g) were used. Infections were initiated
as described previously and when the parasitemia was .10%
rings, mice were treated with AS (256 mg/kg). Twenty-four hours
PT, dormant parasites were collected via cardiac puncture, serially
diluted (4610
6 to 40 dormant parasites/100 ml), and injected IP
(0.1 ml) into experimental mice (n=30 intact and 30 asplenic).
Control mice (n=10 intact and 10 asplenic) were injected with the
lowest (40) and the highest dilution (4610
6) of normal untreated
rings. For these studies, both asplenic and intact mice were used,
so that a comparison between recrudescence rates could be
observed. To minimize batch effects, all experimental mice were
infected on the same day. There were a total of 16 groups
containing five mice each (Table 4).
Statistical analysis
All statistical analyses were carried out using GraphPad Prism 5
(GraphPad Software Inc, La Jolla, CA, USA). All values are
expressed as mean and SD. A p-value of #0.05 was considered
statistically significant. Data were analyzed using one-way
ANOVA with Dunnett’s post-hoc test when comparing treated
group means to an untreated control. The log-rank test was
performed to compare survival rates.
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